Member Info for Saxondale

I've been trying to move shares into my ISA recently , waiting for odd drops to buy again , but it's very hard to buy shares when the price drops . Just about done it now . Although last week the system had the bid higher than the ask for about an hour , for which I was very grateful . Sitting tight now .

Hi, not been here for a while . Was maybe looking to get back in here again , but just for confirmation and sorry for being lazy and not looking up RNS's , but did NCYT not write off the amount owed to them by DHSC , or at least the cost of the products to them ? If they were to lose the case , what effect would it have on their cash position ? They never got paid anyway so its not like they'd have to refund the DHSC ? Thanks

https://www.redeye.se/research/853926/faron-pharmaceuticals-interview-with-ceo-markku-jalkanen-video

More follow up chat here .
Couple of new points of interest -
LLS have initially invested (through placing shares ) $0.5m into Bexmab ( I think he says ) - but they can go up to $5-10m . So Markku sees big potential growth in this relationship.
Expects data in Q4 , as open trial . Very exciting . As dose is 1mg weekly , he is very pleased that dosing is being tolerated well so far .
Funding - CFO is very confident that 2023 will be covered through a variety of options .
Such as increase involvment from LLS or other Investors .
The $20m from IPF to be called off when needed ( subject to conditions being met)
Partnering discussions ongoing .

Traumakine - discussions with DofD also ongoing - this will be a third party funded future - so expect an announcement shorty there he says .

And looks like they haven't had this MHSRS meeting since 2019 - so could be 2-3 years of research they are showcasing .

https://mhsrs.health.mil/SitePages/Sessions.aspx

13th Sept - latest news from 59th Medical wing will present new primate results .
You wouldn't expect them to waste time presenting them if they were useless ?

Odds on that the DofD will be the future of Traumakine for now .
They have a section looking at ARDS treatments too .

Currently I'd say that Traumakine isn't even reflected in the SP at all , at the moment .

Playing the poor relation at the moment , but still there .

Markku again confirmed that Bexmab is going well , and at dosing of 1mg/kg at weekly intervals - so a fairly high level that he expects to achieve results .
Initially with Matins , they were experimenting with 0.1mg and 0.3mg at 3 weekly intervals , and if I remember rightly , they were seeing Bex effective at these low levels , and at the time thought that higher levels would not be necessary .
However , with the soluble Clever-1 discovery , dosing and frequency levels were jacked up to 30mg in order to learn fully what the effects were .
So they look to have settled with 1mg to start . Well within tolerable levels .

The other thing I noticed in these last two interviews - is Markku's passion . He really is 100% involved . No distractions now . I'm not Finnish , but I bet any Finnish viewers would see the passion and commitment standing out from normal reserved interviews . I believe that he can see a clear path to market now , and that is now the overiding driver for the Bex program .
Good on ya !

Glad you are keeping some here TC . But good luck with your other ventures.
We should know by Christmas whether we are headed for the big time , otherwise Cov may be getting his wish .
80-90% of resources being thrown at Bex this year .
It would be a big gamble if they weren't confident of some positive resolution .
Millions of shares owned by the family , a decade of work by the Faron team , reputations at stake .
All this being done at a time when financial markets are in turmoil, the small biotech sector is being decimated , and society in general is facing some of the biggest strains it has seen in decades .

I think they can do it though , hence why I've stuck here so long .

Still got side investments going . AVCT looks like it may blow , and POLX is worth a look with FDA decision next month .
But what do I know , I thought SNG was nailed on .
That taught me a lesson .
But if any of these do hit the jackpot , even a few grand invested will see a massive return - cancelling out all previous crap investment decisions . That's my plan anyway lol
All the best

Yes Luck , soluble clever-1 is a key element , and with Bexmab being a haematological cancer , something they must really have nailed down for sure .
I can't decide whether the huge delay in announcing their findings is good or bad . It obviously wasn't as simple as just increasing dosing to weekly , and seeing levels drop , as that's been going on since January 2021.
I believe they really needed to understand both the role of soluble clever-1 ( as shown in the recent patent application) , and also the correct dosing and frequency of Bex to control it .
They have results and data , but not quite ready for publication .
But to push on with Bexmab ( and also Bexlung starting Q3 also ) , they must be happy enough that they understand enough to draw up protocols of dosing and frequency ( weekly with Bexmab at fairly high dose levels)

The patent last week gave me reassurance that they really are close .

It's possible . Bex has become quite a mission for Markku and the team - and they have become very protective over it .
I believe they passed up on possible offers back in early PII days , as they saw its potential as an enabler for other drugs .
The longer they keep it , and so long as they keep gaining positive knowledge , the more valuable it becomes .
When questioned in the past about selling to one BIg Pharma , he answered by saying that Bex would be almost too important to be owned by just one company . It's potential shouldn't be limited by that .
So the idea of licensing it for various conditions , allowing them to continue trials is something they envisage .
If Bexmab shows good data , that could be the launch of a license deal in the Leukemia sector .

That would solve funding for a good while you'd think .

Hopefully , with FDA meeting this autumn , that also gives them some options too .

Personally , I've had enough placings , and by the looks of it , so has the market and the investors .

Q4 is crunch time . They've got plenty to go with .
I don't think anyone wants a $50 million placing , and I hope it doesn't come to that .

Toni and Markku are well aware of the situation , and I'm quite sure that they have the plan mapped out .

So far , large investors have it seems stuck by their plan . In fact they have increased holdings , and new key investors have joined ( Leukemia organisation) . So , it seems they have their blessing to continue this strategy .

No new stuff that we didn't know , but Markku absolutely is expanding Bexmab sites , so thats a good sign .
Been a while now , so any major adverse events and they wouldn't be doing that .
Toni very relaxed - everything going to plan .
I got the feeling Markku was being very careful with what he said .

Soluble clever 1 - they are still compiling data - don't want to put out something incomplete , but are working hard on fully understanding it before they let the market know .

Everything as we expected . Lets see what future indications Markku and Toni give us today , and Maija tomorrow.
Cash position is good for now at least , funding in place when needed , as are shares for US entry .
Just need some cracking news regarding a partner now please.

I'm in your camp there too thedoors .
We know this is going to be a great share down the road , but the kickings have been brutal .
I'm not fussing over short term SP movements , so long as the plan gets us to where we need to be .
Personally , I've been trading 20-30% of my holding , selling chunks , then buying back lower for the last few months .
Not making money , but at least gaining a few extra shares here and there .
I sold a chunk at 10p last week , so tomorrow maybe another opportunity for me .
I don't hold mega amounts , but enough for it to be important if you know what I mean .
So far , I'm still trusting SD to get the job done , but he does seem to have taken the p*ss somewhat here .
Lets see what transpires tomorrow , and if further revelations make me understand the bigger picture better .

Patent granted yesterday for their SNP responsiveness method .
https://patents.justia.com/patent/11421279
This should add value to the Traumakine package , should they be looking to move forward with some kind of deal .

Perhaps we will get an update tomorrow on this - or at least the plans for Traumakine .

Maybe we will also get hints on progress with -
Bexcombo patient recruitment , sites expansion etc
Soluble clever-1 ( also relating to recently filed patent)
Biomarkers & Staining data , and maybe further long term survival data .
US progress - Boston staff , and US Market preparations

Not expecting huge news , but it's been a while since we heard much , so be good to see what's been going on .

Corporate games being played . At 36p my bum would be a bit squeaky , but to be honest , they've hammered the price down so far now , that at 10p , I'm all out of squeak . The downside risk now is so much lower , and the upside is just getting bigger . Even if we get a takeover squeeze job , it won't be at 10p , so really , just need to sit tight and let it play out .

Telfer needs feeding , can't delay Hav - it's Telfers lifeline .
RNS is a bit fluffy , but SD keeping his powder dry , no need to stick the knife in .
We now keep 30% - happy with that .
SD is a finance guy - with all the tools to get us where we need to be .
Why do you think he's been over to London twice .

Hang in there Drac . Its the long game we are in now .. I'd have lost faith more if Markku hadn't bought more shares this year , along with Timo adding big time .
The patents , the EGM for funding readiness .
The Bexcombo quick set up along with the Leukemia Organisation investment .
Its all going to plan , its just that plan has ended up doing it the 100% on your own way , rather than the accelerated Partnership route .
No good for early SSV , but should pay bigger bucks in the end .
To be honest , the SP is no worse than many of my others , in losing well over 50% since ATH's a few years ago .
However ,if they don't get a result of some significance by the end of Q4 , then we'll need a good explanation why not .

25th - Faron Q&A - after half year Financial report
26th Maija presenting an update on Bex at Biocity Symposium.

A promo tweet reads - Could #bexmarilimab help cancer patients that have no other options? And if so, when? Maija Hollmén might have some news at BioCity Symposium 26 August

https://twitter.com/InFLAMES_Health/status/1559834072888770561?s=20&t=cavUNmBLEAxc3Y-LHoIs4g

InFLAMES is the group that brings research into Immune responses etc ( a founding member of which is Sirpa )

Perhaps just a coincidence , or are we getting some decent update next week ?

Two good opportunities to give investors some update on progress , be that financial , and scientific .

Yes best wishes to your wife Speedy . Sounds like your quick action and A&E saved the day . All the best , and again I appreciate your attitude and outlook , when I do pop on this board . Keep the faith , on all fronts .

Quite a detailed analyst report there .
I'm translating chunks , but it seems they have done a lot of research into Bex potential , spinoffs , and future incomes.

Bexmab looks like the front runner to secure some kind of partnership deal - quickest to market and providing a revenue stream .
Traumakine predictions not included here , as the direction is not yet set , so they can't include any forecast for income as it stands , although news is expected in 2022 as to where its going next .
Haematokine gets quite a bit of attention , again , with the potential for partnerships whilst still in trial and relatively quick entry into market ( compared to some )